Cyr61 is a potential prognostic marker for prostate cancer

作     者：Naoki Terada Prakash Kulkarni Robert H Getzenberg 

作者机构：Department of Urology the James Buchanan Brady Urological Institute The Johns Hopkins University School of Medicine Baltimore M D 21287 USA Department of Urology Oncology The Johns Hopkins University School of Medicine Baltimore Baltimore MD 21287 USA Department of Pharmacology and Molecular Sciences The Johns Hopkins University School of Medicine Baltimore MD 21287 USA 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2012年第14卷第3期

页      面：405-408,I0006页

核心收录：

学科分类：10[医学] 

基　　金：supported by the NCI Prostate Cancer SPORE grant  the Patana Fund of the Brady Urological Institute  and a grant from the Patrick C Walsh Fund of the Brady Urological Institute 

主　　题：Cyr61 lethal prostate cancer non-lethal prostate cancer overdiagnosis overtreatment prostate cancer 

摘      要：Cysteine-rich angiogenic inducer 61 （Cyr61） is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer （PCa）, Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.